Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study

• Status: Completed
• Trial end date: 2002-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of headache response at 2 hours for active treated attacks for increasing dose.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Eletriptan

Criteria

Inclusion Criteria:

• Male and Female subjects in good general health, aged 18 to 65 years.

• Subjects should meet IHS diagnostic criteria for migraine with or without aura.

• Based on past history, subjects should expect to suffer at least one acute attack of migraine with or without aura, each 6 weeks

Exclusion Criteria:

• Known coronary-artery disease, clinically significant arrhythmia, heart failure, or uncontrolled hypertension.

• Pregnant or lactating women.

• Clinically significant electrocardiogram abnormalities at screening.